Man Group
CRSP icon

Man Group’s CRISPR Therapeutics CRSP Stock Holding History

Man Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Sell
73,194
-16,867
-19% -$889K 0.01% 1249
2026
Q1 		$4.28M Buy
90,061
+81,472
+949% +$4.3M 0.01% 1230
2025
Q4 		$450K Buy
+8,589
New +$514K ﹤0.01% 1919
2024
Q2 		– Sell
-109,991
Closed -$7.5M – 2061
2024
Q1 		$7.5M Sell
109,991
-125,885
-53% -$9.01M 0.02% 822
2023
Q4 		$14.8M Buy
+235,876
New +$13M 0.04% 502
2023
Q3 		– Sell
-131,711
Closed -$6.8M – 704
2023
Q2 		$7.39M Buy
+131,711
New +$7.47M 0.02% 735
2022
Q2 		– Sell
-61,690
Closed -$3.63M – 940
2022
Q1 		$3.87M Buy
+61,690
New +$3.87M 0.01% 1000
2021
Q4 		– Sell
-24,759
Closed -$2.77M – 1974
2021
Q3 		$2.77M Buy
+24,759
New +$3.11M 0.01% 1076
2021
Q2 		– Sell
-1,814
Closed -$221K – 1976
2021
Q1 		$221K Sell
1,814
-23,012
-93% -$3.47M ﹤0.01% 1726
2020
Q4 		$3.8M Buy
24,826
+13,120
+112% +$1.55M 0.02% 947
2020
Q3 		$979K Sell
11,706
-73,581
-86% -$6.53M ﹤0.01% 1378
2020
Q2 		$6.27M Buy
85,287
+75,081
+736% +$4.39M 0.03% 567
2020
Q1 		$433K Sell
10,206
-36,188
-78% -$1.87M ﹤0.01% 1310
2019
Q4 		$2.83M Buy
+46,394
New +$2.53M 0.01% 1221
2019
Q2 		– Sell
-50,959
Closed -$1.82M – 1897
2019
Q1 		$1.82M Buy
+50,959
New +$1.76M 0.01% 1375
2018
Q4 		– Sell
-8,821
Closed -$392K – 1951
2018
Q3 		$392K Buy
+8,821
New +$462K ﹤0.01% 1890

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Man Group's CRSP Position: Q2 2026 in Review

Man Group reduced its CRISPR Therapeutics (CRSP) stake by 19% in Q2 2026, selling an estimated $889K and leaving 73,194 shares worth $3.99M. The position accounts for 0.01% of the portfolio, ranked #1249.

Man Group first reported a position in CRSP in Q3 2018 and has held it in 16 quarters since. The position peaked at $14.8M in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Man Group held 73,194 shares of CRISPR Therapeutics worth $3.99M as of Q2 2026.
  • Man Group sold 16,867 CRISPR Therapeutics shares in Q2 2026, an estimated $889K.
  • CRISPR Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #1249 holding.
  • Man Group first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • Man Group's CRISPR Therapeutics position peaked at $14.8M in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.